ArticleMikrochimica acta2026
Label matters: comparing gold nanoparticles and nanoshells with upconversion nanoparticles for quantitative lateral flow immunoassays.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lateral flow immunoassay (LFIA) is a widely used point-of-care method for both qualitative and semi- or fully quantitative detection of clinical biomarkers. There has, however, been limited data available on direct comparison of different types of labels in the LFIA for quantitative analysis using the same non-competitive assay setup. In this study, two groups of antibody-conjugated nanoparticle labels are compared: conventional gold nanostructures with densitometry readout and upconversion nanoparticles (UCNPs) suitable for sensitive luminescence readout. First, the LFIA procedure was optimized using human serum albumin (HSA) as an analyte. In the group of gold-based labels, standard gold nanoparticles were compared with gold nanoshells (AuNSs). In the case of UCNP labels, doping with Er3+ and Tm3+ and surface modifications based on poly(ethylene glycol) and poly(acrylic acid) (PAA) were compared. The best representatives—AuNSs and PAA-Tm UCNPs—were successfully used to detect human serum albumin (HSA) in spiked urine samples. To assess assay versatility, prostate-specific antigen (PSA) was detected in serum. While AuNSs tended to aggregate in serum, the PAA-Tm UCNPs maintained their stability and achieved the limit of detection of 34 pg/mL. Finally, spiked serum samples were analyzed to evaluate detection trueness, achieving a strong correlation with the reference concentrations (recoveries ranging from 82 to 118%). We showed that both label choice and sample matrix are critical: while AuNSs and PAA-Tm UCNPs performed well in urine, PAA-Tm UCNPs excelled in the more complex serum matrix. Thus, PAA-Tm UCNPs were found to be the most suitable labels for biomarker quantitation, highlighting the strong potential of UCNPs for sensitive LFIA applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.